Top
Main

Primary outcome
Peer-reviewed w/exc.
RCT w/exclusions

Feedback
Home
Top  
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Ivermectin for COVID-19: real-time meta analysis of 63 studies
https://ivmmeta.com/
00.250.50.7511.251.51.752+Chowdhury (RCT)81%0.19 [0.01-3.96]14mgviral+0/602/56OT​1 CT​2Improvement, RR [CI]Dose (4d)TreatmentControlEspitia-Hernandez97%0.03 [0.01-0.10]12mgviral+0/287/7CT​2Carvallo85%0.15 [0.02-1.28]36mgdeath1/323/14CT​2Mahmud (DB RCT)27%0.73 [0.60-0.90]12mgrecov. time183 (n)180 (n)CT​2Szente Fonseca-14%1.14 [0.75-1.66]24mghosp.340 (n)377 (n)Cadegiani78%0.22 [0.01-4.48]42mgdeath0/1102/137CT​2Ahmed (DB RCT)85%0.15 [0.01-2.70]48mgsymptoms0/173/19Chaccour (DB RCT)8%0.92 [0.77-1.09]28mgviral+12 (n)12 (n)Ghauri98%0.02 [0.00-0.20]48mgsymptoms37 (n)53 (n)Babalola (DB RCT)49%0.51 [0.29-0.88]24mgviral time20 (n)20 (n)OT​1Ravikirti (DB RCT)89%0.11 [0.01-2.05]24mgdeath0/554/57Bukhari (RCT)82%0.18 [0.07-0.46]12mgviral+4/4125/45Mohan (DB RCT)24%0.76 [0.53-1.09]28mgviral+21/4031/45Biber (DB RCT)45%0.55 [0.27-0.97]36mgviral+13/4721/42Elalfy87%0.13 [0.06-0.27]36mgviral+7/6244/51CT​2López-Me.. (DB RCT)61%0.39 [0.13-1.23]84mgprogression4/20010/198Roy6%0.94 [0.52-1.93]n/arecov. time14 (n)15 (n)CT​2Chahla (CLUS. RCT)87%0.13 [0.03-0.54]24mgno disch.2/11020/144Mourya89%0.11 [0.05-0.25]48mgviral+5/5047/50Loue (QR)70%0.30 [0.04-2.20]14mgdeath1/105/15Merino (QR)74%0.26 [0.11-0.57]24mghosp.population-based cohortFaisal (RCT)68%0.32 [0.14-0.72]48mgno recov.6/5019/50Aref (RCT)63%0.37 [0.22-0.61]n/arecov. time57 (n)57 (n)Krolewiecki (RCT)66%0.34 [0.10-1.16]168mgdecay rate20 (n)14 (n)Vallejos (DB RCT)33%0.67 [0.34-1.28]24mghosp.14/25021/251Together.. (DB RCT)9%0.91 [0.69-1.19]84mghosp./ER86/67795/678Buonfrate (DB RCT)31%0.69 [0.44-1.07]336mgviral load30 (n)29 (n)Mayer55%0.45 [0.32-0.63]151mgdeath3,266 (n)17,966 (n)Tau​2 = 0.29; I​2 = 76.4%Early treatment61%0.39 [0.30-0.52]164/5,818359/20,58261% improvementGorial71%0.29 [0.01-5.76]14mgno recov.0/162/71Improvement, RR [CI]Dose (4d)TreatmentControlKishoria (RCT)-8%1.08 [0.57-2.02]12mgviral+11/197/13Podder (RCT)16%0.84 [0.55-1.12]14mgrecov. time32 (n)30 (n)Khan87%0.13 [0.02-1.00]12mgdeath1/1159/133Chachar (RCT)10%0.90 [0.44-1.83]36mgno recov.9/2510/25Soto-Becerra-39%1.39 [0.88-2.22]14mgdeath47/203401/2,630Rajter (PSM)67%0.33 [0.12-0.84]14mgdeath26/17327/107Hashim (SB RCT)92%0.08 [0.00-1.44]28mgdeath0/596/70CT​2Camprubí-25%1.25 [0.43-3.63]14mgviral+5/134/13Spoorthi21%0.79 [0.64-0.98]n/arecov. time50 (n)50 (n)CT​2Budhiraja99%0.01 [0.00-0.15]n/adeath0/34103/942Okumuş (DB RCT)16%0.84 [0.55-1.30]56mgno improv.16/3019/30Shahbazn.. (DB RCT)19%0.81 [0.67-0.97]14mgrecov. time35 (n)34 (n)Lima-Morales78%0.22 [0.12-0.41]12mgdeath15/48152/287CT​2Gonzalez (DB RCT)-20%1.20 [0.77-1.87]12mghosp. time36 (n)37 (n)Pott-Junior (RCT)-11%1.11 [0.21-5.93]14mgviral+10/271/3Huvemek (DB RCT)32%0.68 [0.38-1.23]84mgno improv.13/5019/50Ahsan50%0.50 [0.28-0.90]21mgdeath17/11017/55CT​2Abd-Elsalam (RCT)25%0.75 [0.17-3.06]36mgdeath3/824/82Hazan93%0.07 [0.00-1.04]24mghosp.0/24syntheticCT​2 SC​4Elavarasi20%0.80 [0.61-1.06]n/adeath48/283311/1,475Tau​2 = 0.15; I​2 = 73.9%Late treatment31%0.69 [0.55-0.88]221/1,897992/6,13731% improvementShouman (RCT)91%0.09 [0.03-0.23]36mgsymp. case15/20359/101Improvement, RR [CI]Dose (1m)TreatmentControlCarvallo96%0.04 [0.00-0.63]14mgcases0/13111/98CT​2Behera54%0.46 [0.29-0.71]42mgcases41/117145/255Carvallo100%0.00 [0.00-0.02]48mgcases0/788237/407CT​2Hellwig (ECO.)78%0.22 [0.05-0.89]14mgcasesecologicalBernigaud99%0.01 [0.00-0.10]84mgdeath0/69150/3,062Alam91%0.09 [0.04-0.25]12mgcases4/5844/60Vallejos73%0.27 [0.15-0.48]48mgcases13/38961/486MD​3Chahla (RCT)84%0.16 [0.04-0.46]48mgcases4/11725/117CT​2Behera83%0.17 [0.12-0.23]42mgcases45/2,199133/1,147Tanioka (ECO.)88%0.12 [0.03-0.51]14mgdeathecologicalSeet (CLUS. RCT)6%0.94 [0.61-1.19]12mgcases398/617433/619OT​1Morgenstern (PSM)74%0.26 [0.10-0.71]56mgcases5/27118/271Mondal88%0.12 [0.01-0.55]n/asymp. case128 (n)1,342 (n)Tau​2 = 1.14; I​2 = 95.4%Prophylaxis85%0.15 [0.08-0.28]525/5,0871,316/7,96585% improvementAll studies60%0.40 [0.33-0.48]910/12,8022,667/34,68460% improvementAll 63 ivermectin COVID-19 primary outcome resultsivmmeta.com Oct 20, 20211 OT: ivermectin vs. other treatment2 CT: study uses combined treatment3 MD: minimal detail available currently4 SC: study uses synthetic control armTau​2 = 0.35; I​2 = 87.5%; Z = 9.44Effect extraction pre-specified, see appendixFavors ivermectinFavors control
Figure S1. Random effects meta-analysis for primary outcomes (as defined before the trial started).
00.250.50.7511.251.51.752+Chowdhury (RCT)81%0.19 [0.01-3.96]14mghosp.0/602/56OT​1 CT​2Improvement, RR [CI]Dose (4d)TreatmentControlEspitia-Hernandez70%0.30 [0.16-0.55]12mgrecov. time28 (n)7 (n)CT​2Mahmud (DB RCT)86%0.14 [0.01-2.75]12mgdeath0/1833/183CT​2Ahmed (DB RCT)85%0.15 [0.01-2.70]48mgsymptoms0/173/19Chaccour (DB RCT)96%0.04 [0.00-1.01]28mgsymptoms12 (n)12 (n)Ghauri98%0.02 [0.00-0.20]48mgsymptoms37 (n)53 (n)Babalola (DB RCT)64%0.36 [0.10-1.27]24mgviral+40 (n)20 (n)OT​1Ravikirti (DB RCT)89%0.11 [0.01-2.05]24mgdeath0/554/57Mohan (DB RCT)62%0.38 [0.08-1.75]28mgno recov.2/406/45Elalfy87%0.13 [0.06-0.27]36mgviral+7/6244/51CT​2Mourya89%0.11 [0.05-0.25]48mgviral+5/5047/50Loue (QR)70%0.30 [0.04-2.20]14mgdeath1/105/15Faisal (RCT)68%0.32 [0.14-0.72]48mgno recov.6/5019/50Aref (RCT)63%0.37 [0.22-0.61]n/arecov. time57 (n)57 (n)Krolewiecki (RCT)-152%2.52 [0.11-58.1]168mgventilation1/270/14Vallejos (DB RCT)-33%1.33 [0.30-5.72]24mgdeath4/2503/251Tau​2 = 0.16; I​2 = 33.4%Early treatment75%0.25 [0.17-0.37]26/978136/94075% improvementPodder (RCT)16%0.84 [0.55-1.12]14mgrecov. time32 (n)30 (n)Improvement, RR [CI]Dose (4d)TreatmentControlChachar (RCT)10%0.90 [0.44-1.83]36mgno recov.9/2510/25Rajter (PSM)46%0.54 [0.27-0.99]14mgdeath13/9824/98Hashim (SB RCT)92%0.08 [0.00-1.44]28mgdeath0/596/70CT​2Camprubí40%0.60 [0.18-2.01]14mgventilation3/135/13Spoorthi21%0.79 [0.64-0.98]n/arecov. time50 (n)50 (n)CT​2Okumuş (DB RCT)33%0.67 [0.27-1.64]56mgdeath6/309/30Shahbazn.. (DB RCT)-197%2.97 [0.13-70.5]14mgdeath1/350/34Lima-Morales78%0.22 [0.12-0.41]12mgdeath15/48152/287CT​2Pott-Junior (RCT)85%0.15 [0.01-1.93]14mgventilation1/271/4Abd-Elsalam (RCT)25%0.75 [0.17-3.06]36mgdeath3/824/82Tau​2 = 0.16; I​2 = 57.2%Late treatment41%0.59 [0.41-0.85]51/932111/72341% improvementShouman (RCT)91%0.09 [0.03-0.23]36mgsymp. case15/20359/101Improvement, RR [CI]Dose (1m)TreatmentControlBehera54%0.46 [0.29-0.71]42mgcases41/117145/255Bernigaud99%0.01 [0.00-0.10]84mgdeath0/69150/3,062Alam91%0.09 [0.04-0.25]12mgcases4/5844/60Chahla (RCT)95%0.05 [0.00-0.80]48mgm/s case0/11710/117CT​2Behera83%0.17 [0.12-0.23]42mgcases45/2,199133/1,147Seet (CLUS. RCT)50%0.50 [0.33-0.76]12mgsymp. case32/61764/619OT​1Morgenstern (PSM)80%0.20 [0.01-4.15]56mghosp.0/2712/271Mondal88%0.12 [0.01-0.55]n/asymp. case128 (n)1,342 (n)Tau​2 = 0.58; I​2 = 87.5%Prophylaxis84%0.16 [0.09-0.31]137/3,779607/6,97484% improvementAll studies70%0.30 [0.22-0.41]214/5,689854/8,63770% improvement36 ivermectin COVID-19 peer reviewed trials after exclusionsivmmeta.com Oct 20, 20211 OT: ivermectin vs. other treatment2 CT: study uses combined treatmentTau​2 = 0.50; I​2 = 80.2%; Z = 7.47Effect extraction pre-specified, see appendixFavors ivermectinFavors control
Figure S2. Random effects meta-analysis for peer-reviewed studies after exclusions. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details.
00.250.50.7511.251.51.752+Chowdhury (RCT)81%0.19 [0.01-3.96]14mghosp.0/602/56OT​1 CT​2Improvement, RR [CI]Dose (4d)TreatmentControlMahmud (DB RCT)86%0.14 [0.01-2.75]12mgdeath0/1833/183CT​2Ahmed (DB RCT)85%0.15 [0.01-2.70]48mgsymptoms0/173/19Chaccour (DB RCT)96%0.04 [0.00-1.01]28mgsymptoms12 (n)12 (n)Babalola (DB RCT)64%0.36 [0.10-1.27]24mgviral+40 (n)20 (n)OT​1Ravikirti (DB RCT)89%0.11 [0.01-2.05]24mgdeath0/554/57Bukhari (RCT)82%0.18 [0.07-0.46]12mgviral+4/4125/45Mohan (DB RCT)62%0.38 [0.08-1.75]28mgno recov.2/406/45Biber (DB RCT)70%0.30 [0.03-2.76]36mghosp.1/473/42Chahla (CLUS. RCT)87%0.13 [0.03-0.54]24mgno disch.2/11020/144Faisal (RCT)68%0.32 [0.14-0.72]48mgno recov.6/5019/50Aref (RCT)63%0.37 [0.22-0.61]n/arecov. time57 (n)57 (n)Krolewiecki (RCT)-152%2.52 [0.11-58.1]168mgventilation1/270/14Vallejos (DB RCT)-33%1.33 [0.30-5.72]24mgdeath4/2503/251Buonfrate (DB RCT)-600%7.00 [0.39-126]336mghosp.4/580/29Tau​2 = 0.06; I​2 = 10.6%Early treatment68%0.32 [0.22-0.48]24/1,04788/1,02468% improvementPodder (RCT)16%0.84 [0.55-1.12]14mgrecov. time32 (n)30 (n)Improvement, RR [CI]Dose (4d)TreatmentControlChachar (RCT)10%0.90 [0.44-1.83]36mgno recov.9/2510/25Hashim (SB RCT)92%0.08 [0.00-1.44]28mgdeath0/596/70CT​2Okumuş (DB RCT)33%0.67 [0.27-1.64]56mgdeath6/309/30Shahbazn.. (DB RCT)-197%2.97 [0.13-70.5]14mgdeath1/350/34Gonzalez (DB RCT)14%0.86 [0.29-2.56]12mgdeath5/366/37Pott-Junior (RCT)85%0.15 [0.01-1.93]14mgventilation1/271/4Huvemek (DB RCT)32%0.68 [0.38-1.23]84mgno improv.13/5019/50Abd-Elsalam (RCT)25%0.75 [0.17-3.06]36mgdeath3/824/82Tau​2 = 0.00; I​2 = 0.0%Late treatment25%0.75 [0.56-1.02]38/37655/36225% improvementShouman (RCT)91%0.09 [0.03-0.23]36mgsymp. case15/20359/101Improvement, RR [CI]Dose (1m)TreatmentControlChahla (RCT)95%0.05 [0.00-0.80]48mgm/s case0/11710/117CT​2Seet (CLUS. RCT)50%0.50 [0.33-0.76]12mgsymp. case32/61764/619OT​1Tau​2 = 1.43; I​2 = 93.0%Prophylaxis84%0.16 [0.04-0.75]47/937133/83784% improvementAll studies60%0.40 [0.27-0.58]109/2,360276/2,22360% improvement27 ivermectin COVID-19 Randomized Controlled Trials after exclusionsivmmeta.com Oct 20, 20211 OT: ivermectin vs. other treatment2 CT: study uses combined treatmentTau​2 = 0.48; I​2 = 65.7%; Z = 4.69Effect extraction pre-specified, see appendixFavors ivermectinFavors control
Figure S3. Random effects meta-analysis for RCT studies after exclusions. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit